Syndax Pharmaceuticals Investor Relations Material
Latest events
Q4 2023
Syndax Pharmaceuticals
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Syndax Pharmaceuticals Inc
Access all reports
Syndax Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company that develops therapies for the treatment of cancer. The Company is engaged in the development and commercialization of novel medicines for cancer. The Company's pipeline includes BTG4-L1, a small molecule that has shown preclinical activity in treating multiple tumor types including breast, ovarian, prostate and central nervous system cancers; and SID418, which has demonstrated remarkable antiviral activity against Ebola virus and related filoviruses. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.
Key slides for Syndax Pharmaceuticals Inc
Study Result
Syndax Pharmaceuticals Inc
Q4 2023
Syndax Pharmaceuticals Inc
Latest articles
Companies That Had Their IPO in 2023: Cautious Optimism
The cautiously optimistic market in 2023 saw stocks rebounded upwards, and interest in IPOs picked up from the previous year.
15 Apr 2024
Puig's 2024 IPO: Paco Rabanne, Jean Paul Gaultier, and Beyond
Explore Puig's journey from its 1914 inception to a 2024 IPO, showcasing its growth, strategic acquisitions, and impact in the beauty and fashion industry.
15 Apr 2024
Alphabet's Unstoppable Rise: From Stanford to Global Tech Leader
Discover Alphabet's rise from a university project to a global tech leader, highlighting its growth, diversification, and visionary leadership.
15 Apr 2024
Ticker symbol
Country
🇺🇸 United States